Global Insomnia Market - Market Research Analysis 2015-2019 with Eisai, Merck, Pfizer, Sanofi & Takeda Dominating

Nov 05, 2015, 11:10 ET from Research and Markets

DUBLIN, Nov. 5, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Global Insomnia Market - Market Research Analysis 2015-2019" report to their offering.

The global insomnia market to decline at a CAGR of 3.08% over the period 2014-2019.

The report includes the present scenario and the growth prospects of the global insomnia market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used for the treatment of insomnia.

The report includes a discussion of the key vendors operating in this market.

Vendors are entering into strategic alliances with other vendors and universities for the research, development, manufacture, and distribution of drugs. The trend is predicted to continue during the forecast period.

According to the report, People's growing awareness of the importance of sleep will motivate individuals with insomnia to seek treatment. The low diagnosis rate for insomnia is due to the lack of awareness and identification of symptoms. Therefore, awareness campaigns and initiatives by hospitals and healthcare centers will help people understand the consequences of sleep disturbances and motivate them to seek treatment, thus driving the global insomnia drugs market.

Further, the report states that the branded drugs indicated for insomnia are expected to lose their patents during the forecast period. Patent expiry is poised to impact the market significantly by slowing down the market's growth rate.

Key vendors

  • Eisai
  • Merck
  • Pfizer
  • Sanofi
  • Takeda

Other prominent vendors

  • Astellas
  • Biocodex
  • Dainippon Sumitomo
  • ECR Pharmaceuticals (Valeant)
  • Fidia Farmaceutici
  • Flynn Pharma
  • Johnson & Johnson
  • Juste
  • Meda

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Insomnia: An overview

Part 06: Market landscape

Part 07: Pipeline portfolio

Part 08: Market segmentation by type of formulation

Part 09: Market segmentation by symptom

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Key vendor analysis

Part 18: Appendix

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets